Inventiva announces randomization of 1st patient in China in the NATiV3 trial

Inventiva announced that the first patient has been randomized in China in the global NATiV3 Phase III clinical trial and provided an update on its clinical development program. Following the randomization of the first patient in China, Inventiva is eligible to receive a $3M milestone payment from Chia Tai Tianqing Pharmaceutical Group or CTTQ . This would be the second of the two short-term milestone payments following the $2 M milestone payment from CTTQ received on July 19 under the license and collaboration agreement with CTTQ. Upon the anticipated receipt in January 2024 of this $3 M milestone, Inventiva is expected to have met all financial and operational conditions precedent required to draw the second EUR 25 M tranche under the finance contract with the European Investment Bank dated May 16, 2022. The Company expects to draw this second tranche in early 2024, following the issuance of warrants to the EIB as provided in the Finance Contract. Lanifibranor was granted Breakthrough Therapy Designation for NASH by China’s National Medical Products Administration,NMPA. Similar to the U.S. Food and Drug Administration’s FDA Breakthrough Therapy Designation, this designation is intended to accelerate the development and review of drugs for serious or life-threatening conditions. The NMPA granted “Breakthrough Therapy Designation” based on the results of Inventiva’s Phase IIb NATIVE clinical trial. Inventiva believes that lanifibranor is the first drug candidate to receive “Breakthrough Therapy Designation” from both the FDA and the NMPA for the treatment of NASH.